These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 15983221

  • 1. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group.
    Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
    [Abstract] [Full Text] [Related]

  • 2. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC, PKC-DRS and PKC-DRS2 Study Groups.
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [Abstract] [Full Text] [Related]

  • 3. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    PKC-DRS2 GroupBeetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. LPAiello@Joslin.Harvard.edu, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [Abstract] [Full Text] [Related]

  • 4. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP, Mbdv Study Group.
    Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
    [Abstract] [Full Text] [Related]

  • 5. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
    Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH, MBDL and MBCU Study Groups.
    Invest Ophthalmol Vis Sci; 2013 Mar 11; 54(3):1750-7. PubMed ID: 23404115
    [Abstract] [Full Text] [Related]

  • 6. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
    PKC-DMES Study Group.
    Arch Ophthalmol; 2007 Mar 11; 125(3):318-24. PubMed ID: 17353401
    [Abstract] [Full Text] [Related]

  • 7. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L, PKC-DRS2 Study Group.
    Invest Ophthalmol Vis Sci; 2009 Jan 11; 50(1):1-4. PubMed ID: 18708615
    [Abstract] [Full Text] [Related]

  • 8. Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.
    Girach A, Aiello LP, Milton RC, Davis MD, Danis RP, Zhi X, Sheetz MJ, Vignati L, PKC-DRS2 Study Group.
    Eye (Lond); 2009 Jan 11; 23(1):209-14. PubMed ID: 18989348
    [Abstract] [Full Text] [Related]

  • 9. Ruboxistaurin: LY 333531.
    Drugs R D; 2007 Jan 11; 8(3):193-9. PubMed ID: 17472415
    [Abstract] [Full Text] [Related]

  • 10. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ, MBBQ Study Group.
    Clin Ther; 2005 Aug 11; 27(8):1164-80. PubMed ID: 16199243
    [Abstract] [Full Text] [Related]

  • 11. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
    Strøm C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M.
    Invest Ophthalmol Vis Sci; 2005 Oct 11; 46(10):3855-8. PubMed ID: 16186374
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
    Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE.
    Invest Ophthalmol Vis Sci; 2006 Jan 11; 47(1):86-92. PubMed ID: 16384948
    [Abstract] [Full Text] [Related]

  • 13. Ruboxistaurin mesilate hydrate for diabetic retinopathy.
    Schwartz SG, Flynn HW, Aiello LP.
    Drugs Today (Barc); 2009 Apr 11; 45(4):269-74. PubMed ID: 19499092
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
    McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL.
    Expert Opin Drug Saf; 2006 Nov 11; 5(6):835-45. PubMed ID: 17044810
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ, Wolka AM, Vinik AI.
    Diabetes Care; 2007 Apr 11; 30(4):896-902. PubMed ID: 17392551
    [Abstract] [Full Text] [Related]

  • 20. Treatment of diabetic retinopathy with protein kinase C subtype Beta inhibitor.
    Lang GE.
    Dev Ophthalmol; 2007 Apr 11; 39():157-165. PubMed ID: 17245085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.